Search results
Results from the WOW.Com Content Network
Ribociclib, sold under the brand name Kisqali, is a medication used for the treatment of certain kinds of breast cancer. [4] Ribociclib is a kinase inhibitor. [ 4 ] It was developed by Novartis and Astex Pharmaceuticals .
The results showed a clinically meaningful increase in medium overall survival of 3.8 months, representing an increase of 33% vs. the temozolomide arm which is currently the standard of care. [57] Kazia PR July 2024
Recent Stage III clinical trial results from the MONALEESA-2 study have indicated that ribociclib in combination with the nonsteroidal aromatase inhibitor letrozole increased median overall survival by 12.5 months in HR+, human epidermal growth factor receptor 2 (HER2)-negative postmenopausal breast cancer patients compared to treatment with ...
Idelalisib, sold under the brand name Zydelig, is a medication used to treat certain blood cancers. [5] [4] Idelalisib acts as a phosphoinositide 3-kinase inhibitor; more specifically, it blocks P110δ, the delta isoform of the enzyme phosphoinositide 3-kinase.
At the time of publication, there was insufficient data on overall survival, and a final analysis is planned after a total of 390 deaths occur per protocol and in agreement with regulatory agencies. Of note, it was noted that the addition of palbociclib caused higher rates of myelotoxic events in the study. [14]
For example, prostate cancer has a much higher one-year overall survival rate than pancreatic cancer, and thus has a better prognosis. Sometimes the overall survival is reported as a death rate (%) without specifying the period the % applies to (possibly one year) or the period it is averaged over (possibly five years), e.g. Obinutuzumab: A ...
The goal is to extend progression survival and overall survival rates. Clinical trials have validated the effectiveness of this approach making it the standard of care for patients. Research by Attal et al has shown that patients with myeloma who undergo HDC experience significantly improved survival rates compared to those receiving ...
Duration of overall response The duration of overall response is measured from the time measurement criteria are met for CR or PR (whichever status is recorded first) until the first date that recurrence or PD is objectively documented, taking as reference for PD the smallest measurements recorded since the treatment started.